8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Welcome once again to Pharm Exec s annual look at what s ahead for the biopharma industry, where we hope the eight trends singled out for this year capture the pulse of change and opportunity impacting leaders and decision-makers in the life sciences the most. From technology and digital hea Powered by WPeMatico Continue reading 8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Identity Crisis: Data Protection Roles for Life Sciences Companies

James Clark The advent of the General Data Protection Regulation (GDPR) has brought with it a complicated range of challenges for businesses operating in life sciences. From transparency and privacy notices, to the use of consent, from contracts with service providers, to extended data Powered by WPeMatico Continue reading Identity Crisis: Data Protection Roles for Life Sciences Companies

EMA Relocation Countdown: Some Industry Viewpoints

July 1, 2018 marked the start of the six-month countdown to the European Medicines Agency (EMA) relocation of its operations to Amsterdam. Worryingly, there remains little guidance or clarity from the EMA as to the implications of the move, and Brexit, on the pharma industry. Three industr Powered by WPeMatico Continue reading EMA Relocation Countdown: Some Industry Viewpoints

Can Trump Plan Serve as Model for What Ails Europe?

Now Donald Trump has at last made his pitch to tackle the challenge of paying for drugs in the US, speculation is rife about what the impact could be around the world and healthcare payers in Europe are combing through his 44-page blueprint to see if any of his ideas might be worth a try locally Powered by WPeMatico Continue reading Can Trump Plan Serve as Model for What Ails Europe?

Growth in the Time of Brexit: James Burt, Accord Healthcare

Accord Healthcare, which acquired Actavis UK and Ireland in 2017, is one of the fastest-growing generic pharmaceutical companies in the UK. It aims to become a Top 5 pan-EMENA (Europe, Middle East and North Africa) generics company by 2021 and has developed a specialty products commercialization Powered by WPeMatico Continue reading Growth in the Time of Brexit: James Burt, Accord Healthcare